LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

Ligand Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

200.01 -0.21

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

197.8

Max

207.35

Pagrindiniai rodikliai

By Trading Economics

Pajamos

47M

4.8M

Pardavimai

70M

115M

P/E

Sektoriaus vid.

92.606

105.69

Pelno marža

4.198

Darbuotojai

68

EBITDA

103M

62M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+18.65% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.5B

4.1B

Ankstesnė atidarymo kaina

200.22

Ankstesnė uždarymo kaina

200.01

Naujienos nuotaikos

By Acuity

28%

72%

70 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-17 18:59; UTC

Pagrindinės rinkos jėgos

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

2025-11-17 23:40; UTC

Rinkos pokalbiai

Gold Consolidates Amid Mixed Signals -- Market Talk

2025-11-17 23:34; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025-11-17 22:58; UTC

Rinkos pokalbiai

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

2025-11-17 22:46; UTC

Rinkos pokalbiai

Risk Assets Set to Have a Strong 2026 -- Market Talk

2025-11-17 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

2025-11-17 22:02; UTC

Uždarbis

Trip.com Group 3Q Rev $2.6B >TCOM

2025-11-17 22:02; UTC

Uždarbis

Trip.com Group 3Q Adj EPS $3.87 >TCOM

2025-11-17 22:02; UTC

Uždarbis

Trip.com Group 3Q EPS $4.02 >TCOM

2025-11-17 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-11-17 21:40; UTC

Uždarbis

James Hardie Industries 2Q Adj EPS 26c >JHX

2025-11-17 21:40; UTC

Uždarbis

James Hardie Industries 2Q Loss/Shr 10c >JHX

2025-11-17 21:39; UTC

Uždarbis

James Hardie Industries 2Q Sales $1.29B >JHX

2025-11-17 21:38; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025-11-17 21:38; UTC

Uždarbis

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

2025-11-17 21:10; UTC

Uždarbis

XP Inc. 3Q EPS BRL2.47 >XP

2025-11-17 21:10; UTC

Uždarbis

XP Inc. 3Q Rev BRL4.67B >XP

2025-11-17 20:20; UTC

Rinkos pokalbiai

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

2025-11-17 20:12; UTC

Rinkos pokalbiai

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

2025-11-17 20:12; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-11-17 20:09; UTC

Rinkos pokalbiai

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

2025-11-17 19:29; UTC

Rinkos pokalbiai

Gold Slide Continues to Start Week -- Market Talk

2025-11-17 19:16; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025-11-17 18:20; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

2025-11-17 16:45; UTC

Įsigijimai, susijungimai, perėmimai

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

2025-11-17 16:16; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025-11-17 16:15; UTC

Uždarbis

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

2025-11-17 15:40; UTC

Įsigijimai, susijungimai, perėmimai

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

2025-11-17 15:22; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

2025-11-17 15:19; UTC

Rinkos pokalbiai

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Akcijų palyginimas

Kainos pokytis

Ligand Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

18.65% į viršų

12 mėnesių prognozė

Vidutinis 238.33 USD  18.65%

Aukščiausias 275 USD

Žemiausias 220 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ligand Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

6

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

102.5 / 109.24Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

70 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat